2024-03-28T20:16:23Z
https://niigata-u.repo.nii.ac.jp/oai
oai:niigata-u.repo.nii.ac.jp:00020026
2022-12-15T03:50:51Z
453:456
471:537:538:1160
Multimodal Treatment of Advanced Neuroblastoma with Intensive Chemotherapy
進行神経芽腫に対する統一プロトコールによる集学的治療の検討
進行神経芽腫に対する統一プロトコールによる集学的治療の検討
岩渕, 眞
123961
大沢, 義弘
123962
内山, 昌則
123963
松田, 由紀夫
123964
内藤, 真一
123965
広田, 雅行
123966
内藤, 万砂文
123967
近藤, 公男
123968
内海, 治郎
123969
浅見, 恵子
123970
笹崎, 義博
123971
小田, 良彦
123972
佐藤, 雅久
123973
advanced neuroblastoma
multimodal treatment
a nationwide single protocol
two-year survival rate
進行神経芽腫
集学的治療
統一治療プロトコール
2年生存率
Twenty-two pediatric patients with a stage IV-A or IV-B neuroblastoma have been treated with multimodal therapy consisting of intensive chemotherapy and surgery at Niigata University Hospital since 1985. The patients first received six cyclic courses of intensive chemotherapy [regimen A_1], consisting of cyclophosphamide [1,200mg/m^2], vincristine [1.5mg/m^2], tetrahydropyranyl adriamycin [pyrarubicin 40mg/m^2], and cisplatin [90mg/m^2]. Primary tumors and involved regional lymph nodes were removed sometime during first six cycles of chemotherapy. After the six cycles of [Regiment A_1], patients received alternating treatment with [Regimen A_2]consisting of cyclophophamide [1,500mg/m^2], THP-adriamycin [50mg/m^2], cisplatin [90mg/m^2], and [Regimen C]consisting of cyclophosphamide [1,500mg/m^2], DTIC [250mg/m^2]. Two-year survival rate was 59%. Nine patients have now survived with disease free at 2 years after initiation of the treatment (survival rate: 41%). From the viewpoint of prognosis, the influencing factors are as follows: small round cell type, diploidy, VMA(-), NSE more than 100ng/ml, N-myc over 8 times of normal value.
departmental bulletin paper
新潟医学会
1993-07
application/pdf
新潟医学会雑誌
7
107
551
558
新潟医学会雑誌
AN00182415
00290440
https://niigata-u.repo.nii.ac.jp/record/20026/files/107(7)_551-558.pdf
jpn